Doxy.me vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
1M+ clinicians 150+ countries; 250K active providers; $50.2M revenue; acquired Telehealth.org/TeleMental Health Institute 2025; TIME HealthTech 2025; Ventures fund; telemedicine leader
About
Doxy.me was founded in 2013 by Brandon Welch in Hawaii with a mission to make telehealth accessible to every clinician and patient, regardless of technical sophistication or budget. The platform was built as a browser-based, zero-download video conferencing solution designed specifically for healthcare — requiring no app installation for patients and offering HIPAA-compliant video sessions out of the box. This simplicity-first approach drove grassroots adoption among solo practitioners and small clinics.\n\nDoxy.me's platform provides HIPAA-compliant video visits, virtual waiting rooms, patient intake forms, group rooms, and integrations with major EHR and practice management systems. Its free tier has been instrumental in driving adoption among independent clinicians who need compliant telehealth without enterprise procurement cycles. Premium tiers add advanced features including custom branding, staff accounts, and analytics. In 2025, Doxy.me acquired Telehealth.org and the TeleMental Health Institute, expanding its educational resources and professional training offerings.\n\nDoxy.me has grown to serve 1M+ clinicians across 150+ countries, with 250,000 active providers using the platform regularly. The company reported $50.2M in annual revenue and was recognized on TIME's HealthTech 2025 list. Its combination of clinical accessibility, global reach, and a freemium model that converts at scale positions Doxy.me as a foundational layer of the global telehealth infrastructure — particularly for solo and small-group practices that larger enterprise platforms overlook.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.